Daniel E. Spratt MD
Chairman and Vincent K Smith Professor, Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OhioDaniel Spratt, MD, is the Vincent K. Smith Professor and Chairman of the Department of Radiation Oncology at University Hospitals Seidman Cancer Center/Case Western Reserve University School of Medicine. Dr. Spratt completed his medical training at Vanderbilt University and residency training in Radiation Oncology at Memorial Sloan Kettering Cancer Center. He joined the faculty at the University of Michigan in 2015 and became the fastest tenured Professor in the University’s history. While at the University of Michigan he was the Chief of the Genitourinary Radiotherapy Program, Associate Chair of Clinical Research, Fellowship Director, the Laurie Snow Endowed Research Professor, Director of Spine Oncology and co-Chair of the Genitourinary Clinical Research Team for the Rogel Cancer Center. Dr. Spratt is an international expert in prostate cancer and served on the national NCCN prostate cancer guidelines committee, serves as the Chair of the Intact Prostate Cancer Subcommittee within NRG Oncology, and serves on the National Cancer Institute’s Genitourinary Steering Committee. He runs an NIH funded translational research team focused on the development and validation of prognostic and predictive biomarkers, has published over 300 peer-reviewed manuscripts, and has served as the principal investigator on numerous national and international clinical trials. He has mentored over 40 students, residents, fellows, and faculty, and has received numerous teaching and mentorship awards.
Disclosures
Dr. Spratt reports the following:- Personal fees: Janssen, AstraZeneca, Blue Earth, Boston Scientific
- Funding, Janssen
Recent Contributions to PracticeUpdate:
- Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer
- Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer
- Natural History of a Second Biochemical Failure After Salvage Radiation Therapy for Prostate Cancer
- Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate Cancer